Compare · INSP vs WST
INSP vs WST
Side-by-side comparison of Inspire Medical Systems Inc. (INSP) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSP and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.59B, about 18.7x INSP ($1.21B).
- WST has been more active in the news (4 items in the past 4 weeks vs 3 for INSP).
- INSP has more recent analyst coverage (25 ratings vs 16 for WST).
- Company
- Inspire Medical Systems Inc.
- West Pharmaceutical Services Inc.
- Price
- $42.03+1.99%
- $320.02+1.78%
- Market cap
- $1.21B
- $22.59B
- 1M return
- -7.87%
- -
- 1Y return
- -69.20%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 4
- Recent ratings
- 25
- 16
Inspire Medical Systems Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest INSP
- SEC Form SD filed by Inspire Medical Systems Inc.
- Inspire Medical Systems downgraded by BofA Securities with a new price target
- Officer Rondoni John sold $114,302 worth of shares (2,641 units at $43.28), decreasing direct ownership by 9% to 27,165 units (SEC Form 4)
- Officer Rondoni John sold $30,107 worth of shares (700 units at $43.01), decreasing direct ownership by 2% to 29,806 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Inspire Medical Systems Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Inspire Medical Systems Inc.
- Director Mccormick Shawn sold $31,536 worth of shares (696 units at $45.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 27,712 units (SEC Form 4)
- SEC Form 144 filed by Inspire Medical Systems Inc.
- SEC Form S-8 filed by Inspire Medical Systems Inc.
- Inspire Medical Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)